The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

Exclusion Criteria

• •Subjects under 30 years or over 85 years of age,
• •Female subjects who are pregnant, lactating, or female subjects who are of childbearing potential who are not using contraceptives,
• •Subjects with metabolic bone diseases such as Paget's disease, hypercalcemia (mild to moderate hypocalcemia is acceptable for entry into the study), moderate to severe vitamin D3 abnormalities (If vitamin D levels are below 16 ng/ml and patient exhibits interest, dietary supplementation will be suggested and levels re-evaluated after 4 weeks and reconsidered for inclusion at that time), any other metabolic bone diseases including osteoporosis,
• •Subjects with prior radiation therapy, bone metastases or other skeletal malignancy,
• •Subjects on medications that would affect bone metabolism,
• •Subjects with growth hormone deficiency,
• •Subjects with uncontrolled diabetes, sprue, inflammatory bowel disease or other disorders that would affect calcium absorption
• •Subjects that are heavy smokers (\> 1 pack/d),
• •Subjects with tetracycline sensitivity or allergy,
• •Subjects on bisphosphonates,
• •Subjects with any form of kidney disease including kidney stones (urolithiasis and nephrolithiasis),
• •Subjects with known allergies to tetracycline and/or demeclocycline,